Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Science Translational Medicine|December 20, 2023
Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients with FOXP3 mutationsŠimon Borna, Esmond Lee, Jason Nideffer, et al.
The Journal of Allergy and Clinical Immunology|February 11, 2014
B-cell development and functions and therapeutic options in adenosine deaminase-deficient patientsImmacolata Brigida, Aisha V Sauer, Francesca Ferrua, et al.
Science Translational Medicine|June 17, 2021
Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell diseaseAnnalisa Lattanzi, Joab Camarena, Premanjali Lahiri, et al.
Science Translational Medicine|September 11, 2015
Hurdles in therapy with regulatory T cellsPiotr Trzonkowski, Rosa Bacchetta, Manuela Battaglia, et al.
Science Translational Medicine|October 27, 2021
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patientsPauline P Chen, Alma-Martina Cepika, Rajni Agarwal-Hashmi, et al.
Blood|May 1, 2016
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiencyMaria Pia Cicalese, Francesca Ferrua, Laura Castagnaro, et al.
Nature Communications|December 22, 2018
Molecular and functional heterogeneity of IL-10-producing CD4+ T cellsLeonie Brockmann, Shiwa Soukou, Babett Steglich, et al.
Blood|April 3, 2015
Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3Jeremy A Goettel, Subhabrata Biswas, Willem S Lexmond, et al.
The Journal of Allergy and Clinical Immunology|September 24, 2022
Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutationMansi Narula, Uma Lakshmanan, Simon Borna, et al.
Lancet (London, England)|June 13, 2016
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trialMaria Sessa, Laura Lorioli, Francesca Fumagalli, et al.
Pageof 20